NASDAQ:ECYT - Endocyte Stock Price, News, Headlines & Rumors

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

Endocyte, Inc. (NASDAQ:ECYT) issued its earnings results on Tuesday, July, 31st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.00. The biopharmaceutical company had revenue of $0.01 million for the quarter. Endocyte had a negative return on equity of 30.87% and a negative net margin of 69,330.66%. View Endocyte's Earnings History.

Endocyte is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for Endocyte.

4 brokers have issued 1 year target prices for Endocyte's shares. Their forecasts range from $21.00 to $21.00. On average, they expect Endocyte's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 23.1% from the stock's current price. View Analyst Price Targets for Endocyte.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endocyte in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Endocyte.

Some companies that are related to Endocyte include Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX) and Akcea Therapeutics (AKCA).

News articles about ECYT stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endocyte earned a daily sentiment score of 0.00 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Endocyte.

Endocyte's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include RA Capital Management LLC (8.07%), BlackRock Inc. (7.44%), Partner Fund Management L.P. (5.81%), FMR LLC (1.27%), Nexthera Capital LP (0.85%) and California Public Employees Retirement System (0.36%). Company insiders that own Endocyte stock include Alison A Armour, Christopher P Leamon and Philip S Low. View Institutional Ownership Trends for Endocyte.

ECYT stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Bank of America Corp DE, TD Asset Management Inc., California Public Employees Retirement System and Dimensional Fund Advisors LP. Company insiders that have sold Endocyte company stock in the last year include Alison A Armour, Christopher P Leamon and Philip S Low. View Insider Buying and Selling for Endocyte.

ECYT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., RA Capital Management LLC, Nexthera Capital LP, FMR LLC, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., Alps Advisors Inc. and Swiss National Bank. View Insider Buying and Selling for Endocyte.

Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ECYT stock can currently be purchased for approximately $17.06.

Endocyte has a market capitalization of $1.12 billion and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Endocyte employs 44 workers across the globe.

Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.